Back to mobile site
Get it on Google Play

Damora starts Phase 1/1b trial of DMR-001 for blood disorders

August 5, 2026 8:01 AM EDT Send to a Friend
Damora Therapeutics (NASDAQ: DMRA) announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial evaluating DMR-001, an investigational monoclonal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login